Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Mannkind Corp (MNKD)

Mannkind Corp (MNKD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
MannKind Expands Executive Leadership Team

MNKD : 6.04 (+0.50%)
MannKind Corporation Reduces Debt by $194 Million and Strengthens Cash Position to Over $180 Million

MannKind Corporation reduces debt by $194 million and increases cash position to over $180 million through note exchanges.Quiver AI SummaryMannKind Corporation has announced a significant reduction in...

MNKD : 6.04 (+0.50%)
MannKind Corporation Announces Exchange of Convertible Notes for Stock and Cash

MNKD : 6.04 (+0.50%)
MannKind Corporation to Discuss Afrezza Diabetes Study Results and Upcoming FDA Meeting Plans

MannKind plans FDA meeting for potential Afrezza supplemental application after positive Phase 3 diabetes study results in youth.Quiver AI SummaryMannKind Corporation announced today that it plans to meet...

MNKD : 6.04 (+0.50%)
MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)

MNKD : 6.04 (+0.50%)
MannKind Corporation and Cipla Ltd. Announce CDSCO Approval for Afrezza Inhalation Powder in India

MannKind's Afrezza inhaled insulin approved in India for diabetes treatment, expected to ship by end of 2025.Quiver AI SummaryMannKind Corporation has announced that India's Central Drugs Standard Control...

MNKD : 6.04 (+0.50%)
MannKind Stock Gains After India Approves Inhaled Insulin: Retail Excitement Builds

This milestone adds India to the list of countries where Afrezza is approved, joining the United States and Brazil.

MNKD : 6.04 (+0.50%)
CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India

MNKD : 6.04 (+0.50%)
Insider Sale: Director at $MNKD (MNKD) Sells 67,536 Shares

Steven B. Binder, a director at $MNKD ($MNKD), sold 67,536 shares of the company on 11-22-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 5.9% of their shares....

MNKD : 6.04 (+0.50%)
MannKind (MNKD) Q3 2024 Earnings Call Transcript

MNKD earnings call for the period ending September 30, 2024.

MNKD : 6.04 (+0.50%)

Barchart Exclusives

Buy Now: 2 Top Dividend Aristocrats With Yields Near 4%
If you love dividends, these two stocks could be good additions to your portfolio. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar